Inactive Instrument

News Oxis International Euronext Paris

Equities

US6918294025

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-

03-26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	03-26	AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	02-01	MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	02-01	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	12-07	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	12-06	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	12-04	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	12-04	CI
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	11-07	AQ
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	11-06	AQ
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	11-06	CI
GT Biopharma Reports Third Quarter 2023 Financial Results	11-01	AQ
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	22/08/23	PU
GT Biopharma Reports Second Quarter 2023 Financial Results	07/08/23	AQ
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023	03/08/23	AQ
GT Biopharma : Submission of Matters to a Vote of Security Holders - Form 8-K	05/07/23	PU
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index	23/06/23	CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index	23/06/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oxis International Euronext Paris

Equities

US6918294025

Summary

Filters